Literature DB >> 16908621

Combined treatment of steroids and cyclosporine in Kimura disease.

Satoshi Sato1, Hisashi Kawashima, Shinji Kuboshima, Kiyoko Watanabe, Yasuyo Kashiwagi, Kouji Takekuma, Akinori Hoshika.   

Abstract

Kimura disease is a rare but distinctive chronic eosinophilic inflammatory disorder that is characterized by tumor-like lesions in the soft tissue and lymph nodes of the head and neck or parotid gland. Recently, many immunopathogenetic features of underlying T lymphocytes and related cytokines have been noted in Kimura disease. However, few previous studies have investigated the serial levels of cytokines in children. In this report we describe an 11-year-old Japanese boy with relapsing Kimura disease. Before the diagnosis of Kimura disease, the patient had a swelling on his left neck. Steroids were effective, but the tumor relapsed within a few months as the steroids were tapered. He was treated with steroids and cyclosporine. This treatment was done by measuring serial levels of serum soluble interleukin-2 receptor, interleukin-4, interleukin-5, and eosinophil cationic protein. These results suggest the activation of T-helper cells and T-helper 2 cytokines, that after activated B cells and eosinophilic infiltration play an important role in Kimura disease, and that cyclosporine suppresses the activity of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908621     DOI: 10.1542/peds.2006-0487

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

1.  Kimura's disease: an unusual glandular involvement with blood and tissue eosinophilia.

Authors:  Arun Saini; Varinder Singh; Jagdish Chandra; Ashok K Dutta
Journal:  Indian J Pediatr       Date:  2009-07-19       Impact factor: 1.967

2.  Kimura's disease: case report of an Italian young male and response to oral cyclosporine A in an 8 years follow-up.

Authors:  Enrico Beccastrini; Giacomo Emmi; Michela Chiodi; Camilla Di Paolo; Elena Benedetta Silvestri; Daniela Massi; Enrico Maggi; Francesco Liotta; Lorenzo Emmi
Journal:  Clin Rheumatol       Date:  2010-04-19       Impact factor: 2.980

3.  Synchronous Kimura lesions at two different sites-a diagnostic dilemma!

Authors:  Gabriel Rodrigues; Bharadwaj Ravi
Journal:  Quant Imaging Med Surg       Date:  2016-04

4.  Kimura's disease with eosinophilic panniculitis--treated with cyclosporine: a case report.

Authors:  Davood Maleki; Alireza Sayyah; Mohammad Hossein Rahimi-Rad; Nasrin Gholami
Journal:  Allergy Asthma Clin Immunol       Date:  2010-03-17       Impact factor: 3.406

5.  Kimura's Disease: A Case Report.

Authors:  Ashok Biradar; Aravind V Patil; Manjunath S Kotennavar; Manjunath Venkatachalaiah
Journal:  Indian J Surg       Date:  2012-10-02       Impact factor: 0.656

6.  Thrombotic storm in Kimura disease.

Authors:  Hong Liu; Samer Z Al-Quran; Richard Lottenberg
Journal:  J Thromb Thrombolysis       Date:  2009-05-26       Impact factor: 2.300

7.  Nephrotic syndrome in Kimura's disease: apropos a case of the glomerular tip lesion in an African-Caribbean male.

Authors:  Rik J B Loymans; Kenrick Berend; Victoria G Abreu de Martinez; Sandrine Florquin; Aiko P J de Vries
Journal:  NDT Plus       Date:  2010-10-04

8.  Remission of secondary membranous nephropathy in a patient with Kimura disease after surgical resection.

Authors:  Sunhwa Lee; Yong Jin Yi; Hyung Ah Jo; Hyuk Huh; Kyung-Hwan Kim; Dong Ki Kim; Hajeong Lee
Journal:  Kidney Res Clin Pract       Date:  2014-08-23

9.  Expression of the interleukin-21 and phosphorylated extracellular signal regulated kinase 1/2 in Kimura disease.

Authors:  Qing-Li Chen; Chen-Xi Li; Bo Shao; Zhong-Cheng Gong; Hui Liu; Bin Ling; Keremu Abasi; Lu-Lu Hu; Bing Wang; Xiao-Peng Yin
Journal:  J Clin Pathol       Date:  2017-01-20       Impact factor: 3.411

Review 10.  Nephrotic syndrome associated with Kimura's disease: a case report and literature review.

Authors:  Song Ren; Xin Yi Li; Fang Wang; Ping Zhang; Yuan Zhang; Gui Sen Li; Li Wang; Xiang Zhong
Journal:  BMC Nephrol       Date:  2018-11-08       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.